Colistin and Polymyxin B: a Re-emergence

Overview

Journal Indian J Crit Care Med

Specialty Critical Care

Date 2009 Nov 3

PMID 19881183

Citations 42

Authors

Sachin Gupta

Deepak Govil

Prem N Kakar

Om Prakash

Deep Arora

Shibani Das

Pradeep Govil

Ashima Malhotra

Affiliations

Soon will be listed here.

Abstract

One of the greatest achievements of modern medicine is the development of antibiotics against life-threatening infections, but the emergence of multidrug-resistant (MDR) gram negative bacteria has drastically narrowed down the therapeutic options against them. This limitation has led clinicians to reappraise the clinical application of polymyxins, an old class of cationic, cyclic polypeptide antibiotics. Polymyxins are active against selected gram-negative bacteria, including the Acinetobacter species, Pseudomonas aeruginosa, Klebsiella species, and Enterobacter species. In this article, we summarise the chemistry, pharmacokinetics, and pharmacodynamics of polymyxins and the latest understanding of their action against MDR pathogens.

Citing Articles

Innovative Strategies and Methodologies in Antimicrobial Peptide Design.

Verma D, Tripathi A, Thakur A J Funct Biomater. 2024; 15(11).

PMID: 39590524 PMC: 11595219. DOI: 10.3390/jfb15110320.

Colistin Susceptibility Testing by Colistin Broth Disk Elution MIC Method among Carbapenem-resistant Gram-negative Blood Culture Clinical Isolates in a Tertiary Care Setting, East Delhi, India.

Nirmal K, Singh N, Sarkar K, Goyal N, Gangar S, Dwivedi A Ethiop J Health Sci. 2024; 33(5):743-750.

PMID: 38784504 PMC: 11111212. DOI: 10.4314/ejhs.v33i5.4.

Retrospective Observational Study to Assess Safety and Tolerability of Nebulized Colistin for the Treatment of Patients With Pneumonia in Real-World Settings in Respiratory ICU.

Talwar D, Prajapat D, Talwar S, Talwar D Cureus. 2024; 16(2):e54652.

PMID: 38524091 PMC: 10959766. DOI: 10.7759/cureus.54652.

Opportunistic etiological agents causing lung infections: emerging need to transform lung-targeted delivery.

Debnath S, Debnath M, Srivastava R Heliyon. 2023; 8(12):e12620.

PMID: 36619445 PMC: 9816992. DOI: 10.1016/j.heliyon.2022.e12620.

Succinyl Chitosan-Colistin Conjugates as Promising Drug Delivery Systems.

Dubashynskaya N, Bokatyi A, Dobrodumov A, Kudryavtsev I, Trulioff A, Rubinstein A Int J Mol Sci. 2023; 24(1).

PMID: 36613610 PMC: 9820547. DOI: 10.3390/ijms24010166.

References

Maddison J, Dodd M, Webb A . Nebulized colistin causes chest tightness in adults with cystic fibrosis. Respir Med. 1994; 88(2):145-7. DOI: 10.1016/0954-6111(94)90028-0. View

Li J, Nation R, Milne R, Turnidge J, Coulthard K . Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2004; 25(1):11-25. DOI: 10.1016/j.ijantimicag.2004.10.001. View

Jones R . Resistance patterns among nosocomial pathogens: trends over the past few years. Chest. 2001; 119(2 Suppl):397S-404S. DOI: 10.1378/chest.119.2_suppl.397s. View

WOLINSKY E, HINES J . Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. N Engl J Med. 1962; 266:759-62. DOI: 10.1056/NEJM196204122661505. View

Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I . Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care. 2003; 7(5):R78-83. PMC: 270720. DOI: 10.1186/cc2358. View

Kasiakou S, Rafailidis P, Liaropoulos K, Falagas M . Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. J Infect. 2005; 50(4):348-52. DOI: 10.1016/j.jinf.2004.05.008. View

Komura S, Kurahashi K . Partial purification and properties of L-2,4-diaminobutyric acid activating enzyme from a polymyxin E producing organism. J Biochem. 1979; 86(4):1013-21. DOI: 10.1093/oxfordjournals.jbchem.a132594. View

Bukhary Z, Mahmood W, Al-Khani A, Al-Abdely H . Treatment of nosocomial meningitis due to a multidrug resistant Acinetobacter baumannii with intraventricular colistin. Saudi Med J. 2005; 26(4):656-8. View

Davis S, Iannetta A, Wedgwood R . Activity of colistin against Pseudomonas aeruginosa: inhibition by calcium. J Infect Dis. 1971; 124(6):610-2. DOI: 10.1093/infdis/124.6.610. View

10.

Berlana D, Llop J, Fort E, Badia M, Jodar R . Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm. 2005; 62(1):39-47. DOI: 10.1093/ajhp/62.1.39. View

11.

Montero A, Corbella X, Ariza J . Clinical relevance of Acinetobacter baumannii ventilator-associated pneumonia. Crit Care Med. 2003; 31(10):2557-9. DOI: 10.1097/01.CCM.0000089937.38406.9F. View

12.

Vasen W, Desmery P, Ilutovich S, Di Martino A . Intrathecal use of colistin. J Clin Microbiol. 2001; 38(9):3523. PMC: 87428. DOI: 10.1128/JCM.38.9.3523-3523.2000. View

13.

Reina R, Estenssoro E, Saenz G, Canales H, Gonzalvo R, Vidal G . Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 2005; 31(8):1058-65. DOI: 10.1007/s00134-005-2691-4. View

14.

Catchpole C, Andrews J, Brenwald N, Wise R . A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother. 1997; 39(2):255-60. DOI: 10.1093/jac/39.2.255. View

15.

Levin A, Barone A, Penco J, Santos M, Marinho I, Arruda E . Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999; 28(5):1008-11. DOI: 10.1086/514732. View

16.

Barnett M, Bushby S, Wilkinson S . SODIUM SULPHOMETHYL DERIVATIVES OF POLYMYXINS. Br J Pharmacol Chemother. 1964; 23:552-74. PMC: 1704012. DOI: 10.1111/j.1476-5381.1964.tb01610.x. View

17.

Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez F, Barrero-Almodovar A, Garcia-Garmendia J, Bernabeu-WittelI M . Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003; 36(9):1111-8. DOI: 10.1086/374337. View

18.

Linden P, Kusne S, Coley K, Fontes P, Kramer D, Paterson D . Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003; 37(11):e154-60. DOI: 10.1086/379611. View

19.

Schindler M, Osborn M . Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry. 1979; 18(20):4425-30. DOI: 10.1021/bi00587a024. View

20.

Bergen P, Li J, Rayner C, Nation R . Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006; 50(6):1953-8. PMC: 1479097. DOI: 10.1128/AAC.00035-06. View